Cara Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) reported Q3 earnings with an EPS of $-0.52, which was in line with estimates. However, revenue decreased by $5.95 million compared to the same period last year. The company's past earnings performance shows a history of mixed results, with EPS misses and beats in previous quarters. The last EPS miss resulted in a slight drop in share price the following day.
November 13, 2023 | 9:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics reported Q3 earnings with an EPS of $-0.52, meeting estimates, but with a significant revenue decline from the previous year.
The in-line EPS may not significantly impact the stock price, but the substantial year-over-year revenue decline could be seen negatively by investors, potentially leading to a short-term decrease in stock price, similar to the slight drop experienced after the last EPS miss.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100